Skip to main content

Advertisement

SpringerLink
Log in

DLC-1 is a candidate biomarker methylated and down-regulated in pancreatic ductal adenocarcinoma

  • Research Article
  • Published:
Tumor Biology

Abstract

Pancreatic ductal adenocarcinoma (PDA) is one of the most aggressive malignancies in humans, and its prognosis is generally poor even after surgery. Many advances have been made to understand the pathogenesis of PDA; however, the molecular mechanisms that lead to pancreatic carcinogenesis are still not clearly understood. The aims of this study were to investigate the relationship between DLC-1 methylation status and clinicopathological characteristics of PDA patients and evaluate the role of DLC-1 methylation status in PDA. The expression of DLC-1 mRNA in PDA tissues was analyzed by real-time PCR. The methylation status of DLC-1 was analyzed by methylation-specific polymerase chain reaction (MSP). Furthermore, we determined the prognostic importance of DLC-1 methylation status in PDA patients. Our results showed that the expression level of DLC-1 mRNA in PDA tissues was lower than that in non-cancerous tissues. The rate of DLC-1 promoter methylation was significantly higher in PDA tissues than in adjacent non-cancerous tissues (p < 0.001). Downregulation of DLC-1 was strongly correlated with promoter methylation (P = 0.003). The presence of DLC-1 methylation in PDA tissue samples was significantly correlated with clinical stage (P = 0.005), histological differentiation (P = 0.05), and lymph node metastasis (P = 0.006). Kaplan–Meier survival analysis showed that DLC-1 methylation status was inversely correlated with overall survival of the PDA patients. Further, Cox multivariate analysis indicated that DLC-1 methylation status was an independent prognostic factor for the overall survival rate of PDA patients. In conclusion, our data suggest that downregulation of DLC-1 may be explained by DNA methylation; DLC-1 may be a biomarker for PDA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Malik NK, May KS, Chandrasekhar R, Wee W, Flaherty L, Iyer R, et al. Treatment of locally advanced unresectable pancreatic cancer: a 10-year experience. J Gastrointest Oncol. 2012;3:326–34. doi:10.3978/j.issn.2078-6891.2012.029.

    PubMed Central  PubMed  Google Scholar 

  2. Kaur S, Baine MJ, Jain M, Sasson AR, Batra SK. Early diagnosis of pancreatic cancer: challenges and new developments. Biomark Med. 2012;6:597–612. doi:10.2217/bmm.12.69.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. McCleary-Wheeler AL, Lomberk GA, Weiss FU, Schneider G, Fabbri M, Poshusta TL, et al. Insights into the epigenetic mechanisms controlling pancreatic carcinogenesis. Cancer Lett. 2013;328:212–21. doi:10.1016/j.canlet.2012.10.005.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Sun C, Ansari D, Andersson R, Wu DQ. Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer? World J Gastroenterol. 2012;18:4944–58. doi:10.3748/wjg.v18.i35.4944.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128:683–92.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Bird AP. CpG-rich islands and the function of DNA methylation. Nature. 1986;321:209–13.

    Article  CAS  PubMed  Google Scholar 

  7. Goelz SE, Vogelstein B, Hamilton SR, Feinberg AP. Hypomethylation of DNA from benign and malignant human colon neoplasms. Science. 1985;228:187–90. doi:10.1126/science.2579435.

    Article  CAS  PubMed  Google Scholar 

  8. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349:2042–54. doi:10.1056/NEJMra023075.

    Article  CAS  PubMed  Google Scholar 

  9. Peng D, Ren CP, Yi HM, Zhou L, Yang XY, Li H, et al. Genetic and epigenetic alterations of DLC-1, a candidate tumor suppressor gene, in nasopharyngeal carcinoma. Acta Biochim Biophys Sin (Shanghai). 2006;38:349–55. doi:10.1111/j.1745-7270.2006.00164.x.

    Article  CAS  Google Scholar 

  10. Ullmannova V, Popescu NC. Expression profile of the tumor suppressor genes DLC-1 and DLC-2 in solid tumors. Int J Oncol. 2006;29:1127–32.

    CAS  PubMed  Google Scholar 

  11. Guan M, Zhou X, Soulitzis N, Spandidos DA, Popescu NC. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications. Clin Cancer Res. 2006;12:1412–9. doi:10.1158/1078-0432.CCR-05-1906.

    Article  CAS  PubMed  Google Scholar 

  12. Song YF, Xu R, Zhang XH, Chen BB, Chen Q, Chen YM, et al. High-frequency promoter hypermethylation of the deleted in liver cancer-1 gene in multiple myeloma. J Clin Pathol. 2006;59:947–51. doi:10.1136/jcp.2005.031377.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Feng X, Li C, Liu W, Chen H, Zhou W, Wang L, et al. DLC-1, a candidate tumor suppressor gene, inhibits the proliferation, migration and tumorigenicity of human nasopharyngeal carcinoma cells. Int J Oncol. 2013;42:1973–84. doi:10.3892/ijo.2013.1885.

    CAS  PubMed  Google Scholar 

  14. Liu H, Shi H, Hao Y, Zhao G, Yang X, Wang Y, et al. Effect of FAK, DLC-1 gene expression on OVCAR-3 proliferation. Mol Biol Rep. 2012;39:10665–70. doi:10.1007/s11033-012-1956-6.

    Article  CAS  PubMed  Google Scholar 

  15. Chen WT, Yang CH, Wu CC, Huang YC, Chai CY. Aberrant deleted in liver cancer-1 expression is associated with tumor metastasis and poor prognosis in urothelial carcinoma. APMIS. 2013. doi:10.1111/apm.12060.

    Google Scholar 

  16. Peng H, Long F, Wu Z, Chu Y, Li J, Kuai R, Zhang J, Kang Z, Zhang X, Guan M. Downregulation of DLC-1 gene by promoter methylation during primary colorectal cancer progression. Biomed Res Int. 2013; 2013: 181384. doi:10.1155/2013/181384.

  17. Guan CN, Zhang PW, Lou HQ, Liao XH, Chen BY. DLC-1 expression levels in breast cancer assessed by qRT- PCR are negatively associated with malignancy. Asian Pac J Cancer Prev. 2012;13:1231–3.

    Article  PubMed  Google Scholar 

  18. Liu JB, Zhang YX, Zhou SH, Shi MX, Cai J, Liu Y, et al. CpG island methylator phenotype in plasma is associated with hepatocellular carcinoma prognosis. World J Gastroenterol. 2011;17:4718–24. doi:10.3748/wjg.v17.i42.4718.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Feng M, Huang B, Du Z, Xu X, Chen Z. DLC-1 as a modulator of proliferation, apoptosis and migration in Burkitt's lymphoma cells. Mol Biol Rep. 2011;38(3):1915–20. doi:10.1007/s11033-010-0311-z.

    Article  CAS  PubMed  Google Scholar 

  20. Zhang T, Zheng J, Jiang N, Wang G, Shi Q, Liu C, et al. Overexpression of DLC-1 induces cell apoptosis and proliferation inhibition in the renal cell carcinoma. Cancer Lett. 2009;283:59–67. doi:10.1016/j.canlet.2009.03.025.

    Article  CAS  PubMed  Google Scholar 

  21. Zhang T, Zheng J, Liu C, Lu Y. Expression of DLC-1 in clear cell renal cell carcinoma: prognostic significance for progression and metastasis. Urol Int. 2009;82:380–7. doi:10.1159/000218524.

    Article  CAS  PubMed  Google Scholar 

  22. Jin Z, Mori Y, Yang J, Sato F, Ito T, Cheng Y, et al. Hypermethylation of the nel-like 1 gene is a common and early event and is associated with poor prognosis in early-stage esophageal adenocarcinoma. Oncogene. 2007;26:6332–40. doi:10.1038/sj.onc.1210461.

    Article  CAS  PubMed  Google Scholar 

  23. Sun D, Zhang Z, Van do N, Huang G, Ernberg I, Hu L. Aberrant methylation of CDH13 gene in nasopharyngeal carcinoma could serve as a potential diagnostic biomarker. Oral Oncol. 2007;43:82–7.

    Article  CAS  PubMed  Google Scholar 

  24. Brock MV, Gou M, Akiyama Y, Muller A, Wu TT, Montgomery E, et al. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res. 2003;9:2912–9.

    CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Gastroenterology, The Third Hospital Affiliated to Nantong University, No. 585, Xingyuan North Rd., Wuxi, 214041, Jiangsu, China

    Yu-Zheng Xue, Tie-Long Wu, Yan-Min Wu, Ying-Yue Sheng, Zhe-Qiang Wei, Yu-Feng Lu, Li-Hua Yu & Jian-Ping Li

  2. Department of Gastroenterology, Changhai Hospital of Second Military Medical University, No. 168, Changhai Rd., Shanghai, 200001, China

    Zhao-Shen Li

Authors
  1. Yu-Zheng Xue
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tie-Long Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yan-Min Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ying-Yue Sheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhe-Qiang Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yu-Feng Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Li-Hua Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jian-Ping Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Zhao-Shen Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Yu-Zheng Xue, Jian-Ping Li or Zhao-Shen Li.

Additional information

Yu-Zheng Xue, Tie-Long Wu, and Yan-Min Wu contributed equally to this paper.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xue, YZ., Wu, TL., Wu, YM. et al. DLC-1 is a candidate biomarker methylated and down-regulated in pancreatic ductal adenocarcinoma. Tumor Biol. 34, 2857–2861 (2013). https://doi.org/10.1007/s13277-013-0846-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-013-0846-4

Keywords

Search

Navigation